Predicting the Grade of Meningiomas by Clinical–Radiological Features: A Comparison of Precontrast and Postcontrast MRI

Phase 1, Open-Label, Dose-Escalation Study on the Safety, Pharmacokinetics, and Preliminary Efficacy of Intravenous Coxsackievirus A21 (V937), With or Without Pembrolizumab, in Patients With Advanced Solid Tumors

Association of Polypharmacy and Potential Drug-Drug Interactions With Adverse Treatment Outcomes in Older Adults With Advanced Cancer

The Antitumor Activity of Human Vγ9Vδ2 T Cells is Impaired by TGF-Β through Significant Phenotype, Transcriptomic, and Metabolic Changes

Neoadjuvant Pembrolizumab in Localized MSI-H/dMMR Solid Tumors

Mitochondrial Related Genome-Wide Mendelian Randomization Identifies Putatively Causal Genes for Multiple Cancer Types

Novel Therapy Afamitresgene Autoleucel Shows Early Potential for Antitumor Activity

Predicting the Grade of Meningiomas by Clinical–Radiological Features: A Comparison of Precontrast and Postcontrast MRI

header-info

Dec, 01, 2022

An accessible risk-scoring model based on the demographic characteristics and radiological features of precontrast MRI is sufficient to distinguish between low-grade and high-grade meningiomas, with a performance equal to that of a full MRI, based on radiological features.